Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at UCLA Health

Sites in Los Angeles, CA

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 5:18 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1098
Shown on this page
12
Current sort
Recently updated
Campus scope
UCLA Health, Los Angeles, CA
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within UCLA Health, Los Angeles, CA. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 481–492 of 1,098 matching trials with a site at UCLA Health, Los Angeles, CA.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Recruiting Phase 2 Interventional

A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

NCT06842498
Status at this site: Recruiting
View directory record Official record
Conditions
Metastatic Castration-Resistant Prostate Cancer
Interventions
FG-3246
Drug
Lead sponsor
Kyntra Bio
Industry
Eligibility
18 Years and older · Male only
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
23
States / cities
Goodyear, Arizona • Scottsdale, Arizona • Tucson, Arizona + 18 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 29, 2026, 5:18 PM EDT
Active, not recruiting Phase 3 Interventional

Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer, INNOVATE Trial

NCT04134260
Site status not listed — check the official record
View directory record Official record
Conditions
Prostate Adenocarcinoma, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
Interventions
Apalutamide, Biospecimen Collection, Bone Scan, Computed Tomography, Hormone Therapy, Magnetic Resonance Imaging, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire Administration, Radiation Therapy
Drug · Procedure · Other + 1 more
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older · Male only
Enrollment
586 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2031
U.S. locations
348
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Anaheim, California + 259 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 29, 2026, 5:18 PM EDT
Active, not recruiting Not applicable Interventional

Evaluation of Safety and Effectiveness of Stryker Surpass Evolve™ Flow Diverter System

NCT04195568
Site status not listed — check the official record
View directory record Official record
Conditions
Aneurysm, Intracranial
Interventions
Surpass Evolve Flow Diverter System
Device
Lead sponsor
Stryker Neurovascular
Industry
Eligibility
18 Years to 80 Years
Enrollment
248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
32
States / cities
Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 27 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 29, 2026, 5:18 PM EDT
Recruiting No phase listed Observational

Safety Study to Evaluate the Occurrence of EFAD in Pediatric Patients With PNAC Who Require More Than Eight Weeks of Omegaven Treatment

NCT06274788
Status at this site: Recruiting
View directory record Official record
Conditions
Parenteral Nutrition Associated Liver Disease (PNALD), Essential Fatty Acid Deficiency, Malnutrition, Pediatric ALL
Interventions
Omegaven® (fish oil triglycerides) Injectable Emulsion
Drug
Lead sponsor
Fresenius Kabi
Industry
Eligibility
1 Day to 17 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
10
States / cities
Fountain Valley, California • Los Angeles, California • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 29, 2026, 5:18 PM EDT
Recruiting Phase 1Phase 2 Interventional

Study of the Pharmacokinetics and Safety of Glecaprevir/Pibrentasvir Initiated in Pregnancy in Women With Hepatitis C With and Without HIV

NCT07040319
Status at this site: Not yet recruiting
View directory record Official record
Conditions
Hepatitis C
Interventions
Glecaprevir/pibrentasvir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
16 Years to 45 Years · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
10
States / cities
Los Angeles, California • Aurora, Colorado • Jacksonville, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 29, 2026, 5:18 PM EDT
Active, not recruiting Phase 3 Interventional

Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)

NCT06074588
Site status not listed — check the official record
View directory record Official record
Conditions
Non-small Cell Lung Cancer (NSCLC)
Interventions
Sacituzumab tirumotecan, Docetaxel, Pemetrexed
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
556 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
16
States / cities
Los Angeles, California • Jacksonville, Florida • Orange City, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 29, 2026, 5:18 PM EDT
Not yet recruiting Phase 3 Interventional

Long-Term Efficacy Study of Vatiquinone for the Treatment of Friedreich's Ataxia (FA)

NCT07681713
Site status not listed — check the official record
View directory record Official record
Conditions
Friedreich's Ataxia
Interventions
Vatiquinone
Drug
Lead sponsor
PTC Therapeutics
Industry
Eligibility
7 Years to 21 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
4
States / cities
Los Angeles, California • Tampa, Florida • Iowa City, Iowa + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 29, 2026, 5:18 PM EDT
Active, not recruiting Phase 1 Interventional

Precision-T: A Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies

NCT04013685
Site status not listed — check the official record
View directory record Official record
Conditions
Acute Myeloid Leukemia, Acute Lymphoid Leukemia, Myelodysplastic Syndromes, Acute Leukemia, Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), Chronic Myeloid Leukemia
Interventions
Orca-T
Biological
Lead sponsor
Orca Biosystems, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
21
States / cities
Duarte, California • Los Angeles, California • Sacramento, California + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 29, 2026, 5:18 PM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Safety and Tolerability of AD-NP1 in Healthy Human Adult Volunteers

NCT07762001
Site status not listed — check the official record
View directory record Official record
Conditions
Maximum Tolerated Dose, Dose Escalation
Interventions
AD-NP1, Placebo
Drug
Lead sponsor
Arjun Deb, MD
Other
Eligibility
21 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 29, 2026, 5:18 PM EDT
Not yet recruiting Not applicable Interventional

Screening Cardiometabolic Opportunities Using Transformative Echocardiography Artificial Intelligence (SCOUT Echo-AI)

NCT07216859
Site status not listed — check the official record
View directory record Official record
Conditions
MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, Cirrhosis
Interventions
AI-Enabled Identification (EchoNet-Liver)
Other
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2028
U.S. locations
6
States / cities
Los Angeles, California • Palo Alto, California • Pleasanton, California + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 29, 2026, 5:18 PM EDT
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) for Prevention of HIV in People Who Inject Drugs (HPTN 103)

NCT06101342
Site status not listed — check the official record
View directory record Official record
Conditions
Pre-Exposure Prophylaxis of HIV Infection
Interventions
Lenacapavir Injection, Lenacapavir Tablet, Emtricitabine/tenofovir disoproxil fumarate (F/TDF)
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
181 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
9
States / cities
Los Angeles, California • San Diego, California • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 29, 2026, 5:18 PM EDT
Recruiting No phase listed Observational

Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease Prospective Outcomes Registry

NCT01915511
Status at this site: Recruiting
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
21 Years and older
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2031
U.S. locations
47
States / cities
Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 38 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 29, 2026, 5:18 PM EDT

About this UCLA Health institution page

What this page lists
ClinicalTrials.gov records that list UCLA Health in Los Angeles, CA as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, browse by condition, or browse by U.S. city.